Spruce Biosciences annual return on equity
2020
2021
2022
2023
2024
2025
Spruce Biosciences Return on Equity (ROE) Growth & History (SPRB)
Spruce Biosciences's return on equity was −109.24% for fiscal 2025.
View full Spruce Biosciences company overviewSpruce Biosciences annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −109.24% | −8.54 pp |
| 2024 | 2024-12-31 | −100.70% | −34.61 pp |
| 2023 | 2023-12-31 | −66.10% | −14.75 pp |
| 2022 | 2022-12-31 | −51.35% | −18.92 pp |
| 2021 | 2021-12-31 | −32.43% | +17.30 pp |
| 2020 | 2020-12-31 | −49.73% | — |
Spruce Biosciences quarterly return on equity
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −27.42% | −12.92 pp |
| Q1 2026 | 2026-03-31 | −31.79% | +31.82 pp |
| Q4 2025 | 2025-12-31 | −61.15% | −2.59 pp |
| Q3 2025 | 2025-09-30 | −88.46% | −72.81 pp |
| Q2 2025 | 2025-06-30 | −14.50% | +0.09 pp |
| Q1 2025 | 2025-03-31 | −63.61% | −47.37 pp |
| Q4 2024 | 2024-12-31 | −58.56% | −46.27 pp |
| Q3 2024 | 2024-09-30 | −15.65% | −2.07 pp |
| Q2 2024 | 2024-06-30 | −14.60% | −2.06 pp |
| Q1 2024 | 2024-03-31 | −16.24% | −1.75 pp |
| Q4 2023 | 2023-12-31 | −12.29% | +2.87 pp |
| Q3 2023 | 2023-09-30 | −13.58% | +0.03 pp |
| Q2 2023 | 2023-06-30 | −12.54% | +0.00 pp |
| Q1 2023 | 2023-03-31 | −14.50% | −3.38 pp |
| Q4 2022 | 2022-12-31 | −15.17% | −7.22 pp |
| Q3 2022 | 2022-09-30 | −13.61% | −4.44 pp |
| Q2 2022 | 2022-06-30 | −12.54% | −3.84 pp |
| Q1 2022 | 2022-03-31 | −11.12% | −4.30 pp |
| Q4 2021 | 2021-12-31 | −7.95% | +9.07 pp |
| Q3 2021 | 2021-09-30 | −9.16% | — |
| Q2 2021 | 2021-06-30 | −8.69% | — |
| Q1 2021 | 2021-03-31 | −6.82% | — |
| Q4 2020 | 2020-12-31 | −17.02% | — |
Spruce Biosciences return on equity trends
Over the last five fiscal years, Spruce Biosciences's return on equity decreased from −49.73% to −109.24%, a change of −59.51 percentage points. The latest reported quarter, Q2 2026, shows −27.42%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Spruce Biosciences source filings ↗